Venetoclax and Bomedemstat in Patients with Relapsed/Refractory Acute Myeloid Leukemia
This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.
Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Acute Myeloid Leukemia, in Relapse
DRUG: Bomedemstat|DRUG: Venetoclax
Incidence of Treatment-Emergent Toxicity, Toxicity is defined as including dose limiting toxicities (DLTs), serious adverse events (SAEs) and adverse events (AEs) in study participants. Toxicity will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion., Up to 72 weeks|Recommended Phase 2 Dose (RP2D), The RP2D of combination VenBom therapy will be determined as the maximum tolerated dose of study treatment as assessed by treating physician using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., Up to 72 weeks
Overall Response Rate (ORR), Rate of participants achieving complete response (CR), CR with incomplete neutrophil or platelet recovery (CRi), CR with incomplete hematologic recovery (CRh), partial remission (PR), or morphologic leukemia free state (MLFS) response to study treatment. Response will be assessed by treating physician using the modified 2017 European LeukemiaNet (ELN) AML Response Criteria., Up to 72 weeks|Proportion of Participants with Measurable Residual Disease, Proportion of patients with measurable residual disease (MRD) evaluated by multiparameter flow cytometry (MFC) at each bone marrow aspirate collection., Up to 72 weeks
This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.